Protocol Ledger

NCT05951179 · Phase II · RECRUITING

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Interventional Phase II clinical trial protocol NCT05951179 sponsored by Protara Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-09-15 Enrollment: 131 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05951179
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)131 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05951179
Protocol FieldVerified Registry Value
NCT IdentifierNCT05951179
Consolidated Lead SponsorProtara Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment131 participants (ESTIMATED)
Registered Start Date2023-09-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05951179
Hospital Research SiteLocationSite Profile
Mayo Clinic ArizonaPhoenix, AZOpen Hospital Dossier ->
UCI Health and Chao Family Comprehensive Cancer CenterOrange, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI